Platelet growth factors: potential impact on transfusion medicine.
Kuter
D J
DJ
Clinical Hematology Department, Massachusetts General Hospital, Boston 02114, USA.
Cebon
J
J
Harker
L A
LA
Petz
L D
LD
McCullough
J
J
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001771:Blood Banks / Q000458:organization & administration; D001792:Blood Platelets / Q000187:drug effects*; D005544:Forecasting; D006410:Hematopoiesis / Q000187:drug effects; D016298:Hematopoietic Cell Growth Factors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D017370:Interleukin-11 / Q000009:adverse effects / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use; D008533:Megakaryocytes / Q000166:cytology / Q000187:drug effects*; D009369:Neoplasms / Q000097:blood / Q000628:therapy; D010976:Platelet Count / Q000187:drug effects; D017713:Platelet Transfusion / Q000191:economics; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011323:Primates; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000628:therapy; D013926:Thrombopoietin / Q000009:adverse effects / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use
D016298:Hematopoietic Cell Growth Factors; D017370:Interleukin-11; D011994:Recombinant Proteins; C103117:polyethylene glycol-recombinant human megakaryocyte growth and development factor; D011092:Polyethylene Glycols; D013926:Thrombopoietin